Physician profile
Gregory B Cartwright
NPI 1912957499
$2,087.34
in general payments reported to CMS, 2019-2025
29 companies · $534 in 2025
The $534 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.63 · 2023: $36.89 · 2024: $1,504 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.49 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $356.23 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $204.28 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $190.57 | 2023-2024 | Belbuca |
| Glaxosmithkline, LLC. | $154.97 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $142.55 | 2024-2025 | |
| Lilly USA, LLC | $115.96 | 2024 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.00 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Amgen INC. | $92.62 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $79.23 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $76.75 | 2024-2025 | Rexulti |
| Azurity Pharmaceuticals, INC. | $71.47 | 2024-2025 | Horizant |
| Exact Sciences Corporation | $67.80 | 2024-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $63.37 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Abbott Laboratories | $37.68 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $37.18 | 2024-2025 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $35.81 | 2024-2025 | Gemtesa |
| Lundbeck LLC | $33.67 | 2024 | Rexulti |
| Harmony Biosciences LLC | $26.64 | 2025 | |
| Astellas Pharma US INC | $20.75 | 2024 | Veozah |
| Vertex Pharmaceuticals Incorporated | $19.88 | 2025 | |
| Dexcom, INC. | $19.36 | 2024 | Dexcom G6 Transmitter |
| Valinor Pharma, LLC | $19.20 | 2024 | Movantik |
| Medtronic, INC. | $18.86 | 2024 | Intellis Adaptivestim |
| Phathom Pharmaceuticals, INC. | $18.68 | 2024 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.74 | 2024 | Jardiance |
| Merck Sharp & Dohme LLC | $17.35 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Protega Pharmaceutials INC | $16.00 | 2025 | Roxybond |
| Idorsia Pharmaceuticals US INC | $15.11 | 2024 | Quviviq |
| Mission Pharmacal Company | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cartwright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.